Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer von Armstrong, Andrew J, Halabi, Susan, Healy, Patrick, Alumkal, Joshi J, Winters, Carolyn, Kephart, Julie, Bitting, Rhonda L, Hobbs, Carey, Soleau, Colleen F, Beer, Tomasz M, Slottke, Rachel, Mundy, Kelly, Yu, Evan Y, George, Daniel J

Volltext